Humane Cosmetics Act of 2025
- Sponsor
- Rep. Beyer, Donald S. [D-VA-8]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Feb 27, 2025
Bottom line
The Humane Cosmetics Act of 2025 aims to end cosmetic animal testing and the sale of animal-tested cosmetics in the U.S., aligning federal law with international standards and state-level prohibitions while providing limited exemptions.
What it actually does
This bill prohibits the conduct or contracting of cosmetic animal testing within the United States and bans the sale or transport in interstate commerce of any cosmetic product developed or manufactured using such testing, effective one year after enactment. It also restricts the use of animal testing data for safety assessments, with specific exemptions for foreign regulatory compliance, Secretary-requested testing under strict conditions, and testing for drug or non-cosmetic purposes. The bill establishes civil penalties for violations and preempts conflicting state laws.
Proponents argue
Proponents argue that this bill is a crucial step towards modernizing cosmetic safety assessment by promoting the use of advanced non-animal testing methods, which are often more accurate and humane. They contend it aligns the U.S. with a growing number of countries and states that have already banned such practices, satisfying consumer demand for cruelty-free products and enhancing the ethical standing of the American cosmetics industry. Supporters emphasize that the exemptions are carefully crafted to ensure public safety remains paramount while phasing out unnecessary animal cruelty.
Opponents contend
Opponents, if any, might express concerns that a broad ban on animal testing, even with exemptions, could potentially compromise consumer safety by limiting the available methods for assessing product ingredients, especially for novel compounds. They might argue that the transition to non-animal alternatives could be costly and time-consuming for manufacturers, potentially stifling innovation or increasing product prices. Some could also raise concerns about the practicalities of enforcing the ban across complex global supply chains and the potential for competitive disadvantages for U.S. companies if foreign markets still require animal testing.
The bill is concise and relatively straightforward, allowing an informed reader to understand its core provisions and implications within the typical time allotted for legislative review.
Section 2(a)
Prohibition on Cosmetic Animal Testing
This provision makes it illegal to knowingly conduct or contract for cosmetic animal testing within the United States. This ban takes effect one year after the bill becomes law, directly targeting the practice of using live non-human vertebrates to test cosmetic products or ingredients for safety or efficacy.
Supporters argue
Supporters argue this prohibition is the core of the bill, directly addressing the ethical concerns surrounding animal cruelty in cosmetic development. They contend that modern science offers sufficient non-animal alternatives, making such testing unnecessary and outdated.
Critics contend
No specific opposition is typically raised against the concept of prohibiting animal testing in the U.S. when robust alternatives are available, but some might express concerns about the timeline for transition or the scope of exemptions.
Tradeoffs
The provision balances the ethical imperative to protect animals with the industry's need for reliable safety testing. The one-year grace period aims to provide time for transition to alternative methods.
Section 2(b)
Prohibition on Sale or Transport of Animal-Tested Cosmetics
This section prohibits the knowing sale, offer for sale, or transport in interstate commerce within the United States of any cosmetic product that was developed or manufactured using cosmetic animal testing conducted by anyone in its supply chain after the effective date. This extends the ban beyond just testing to the market availability of such products.
Section 2(c)
Restrictions on Data Use for Safety Assessment
This provision stipulates that evidence from animal testing conducted after the bill's effective date cannot be used to establish the safety of a cosmetic, ingredient, or nonfunctional constituent under the Federal Food, Drug, and Cosmetic Act. It includes specific exceptions, such as for testing subject to exemptions under subsection (d)(2) (Secretary-requested testing) or for ingredients where no non-animal alternative exists and the testing falls under other specific exemptions (d)(3) or (d)(4), with documented non-cosmetic intent and prior non-cosmetic use.
Section 2(d)(1)
Exemption for Foreign Regulatory Compliance
This exemption allows animal testing to be conducted outside the United States if it is necessary to comply with a requirement from a foreign regulatory authority. This means a company can still test on animals for products intended for sale in countries where such testing is mandated, without violating the U.S. ban, as long as the testing occurs outside U.S. borders.
Section 2(d)(2)
Exemption for Secretary-Requested Testing
This exemption permits the Secretary of Health and Human Services (via the FDA) to request, require, or conduct animal testing under very specific and stringent conditions. These conditions include a written finding that no non-animal alternative exists, information of adverse health effects (beyond minor reactions), and that the ingredient cannot be replaced. This finding must be published for public comment, and the Secretary must make a written determination that no existing data can substitute for new animal testing.
Section 2(g)
Preemption of State Authority
This provision establishes that no state or political subdivision can create or maintain any prohibition or regulation related to cosmetic animal testing or data use that is not identical to the federal prohibitions and exemptions set forth in this Act. It also prevents states from requiring animal testing not permitted by the federal law, effectively creating a uniform national standard.
This sub-clause allows the use of animal testing data for an ingredient or nonfunctional constituent if there is no non-animal alternative, the testing is subject to an exemption under subsection (d)(4) (non-cosmetic purposes), there is documented evidence of the non-cosmetic intent of the test, and there is a history of use of the ingredient outside of cosmetics at least 1 year prior to reliance on the evidence.
Section 2(c)(1)(B)(ii)(II)
Why it matters:The complexity is likely due to the need to precisely define the narrow circumstances under which animal testing data, even if conducted for non-cosmetic purposes, can be leveraged for cosmetic safety assessments, reflecting a careful legislative attempt to close loopholes while acknowledging existing data.
Case for: Supporters would argue this provision is a practical and necessary carve-out, allowing the use of existing, relevant safety data for ingredients already in use in other sectors (e.g., pharmaceuticals, industrial chemicals) without requiring new, redundant non-animal testing for cosmetic applications, especially when non-animal alternatives are not yet established.
Case against: Animal welfare advocates might argue that even with these restrictions, it still allows animal-derived data to inform cosmetic safety, potentially creating an indirect incentive for animal testing in related fields, or that the 'non-cosmetic intent' could be difficult to verify definitively.
Estimated impact: This provision could significantly impact the introduction of new ingredients that have dual uses (cosmetic and non-cosmetic) by setting clear, albeit complex, rules for how their existing safety data can be utilized.
Defines 'nonfunctional constituent' by referencing section 701.3(l) of title 21, Code of Federal Regulations, as it exists on the date of enactment. This definition is crucial for understanding the scope of the data use restrictions and exemptions.
Section 2(h)(3)
Why it matters:Referencing existing CFR definitions is standard legislative practice to ensure consistency with current regulatory frameworks and avoid redefining terms already established in law.
Case for: The case for this is clarity and consistency, ensuring that the bill's provisions apply to incidental ingredients (like impurities or byproducts) in a manner consistent with how they are already regulated, preventing unintended consequences or regulatory gaps.
Case against: No specific case against this technical definition, as it serves to clarify the scope of the bill's application rather than introduce new policy. However, any future changes to 21 CFR 701.3(l) would not automatically apply to this Act, potentially creating divergence over time.
Estimated impact: This definition clarifies which minor components of cosmetic products are subject to the animal testing data restrictions, ensuring comprehensive coverage of all relevant substances within a cosmetic formulation.